Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

BET Inhibition Induces Apoptosis in Aggressive B-Cell Lymphoma via Epigenetic Regulation of BCL-2 Family Members

12 Jul 2016

Abstract excerpt

Targeting BET bromodomain proteins using small molecules is an emerging anticancer strategy with clinical evaluation of at least six inhibitors now underway. Although MYC downregulation was initially proposed as a key mechanistic property of BET inhibitors, recent evidence suggests that additional antitumor activities are important. Using the Eμ-Myc model of B-cell lymphoma, we demonstrate that BET inhibition...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Multiple Myeloma Research and Treatments
Share to Protein Degradation and Inhibitors
Share to Ubiquitin and proteasome pathways

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 27406984
DOI: 10.1158/1535-7163.mct-15-0924

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

BET Inhibition Induces Apoptosis in Aggressive B-Cell Lymphoma via Epigenetic Regulation of BCL-2 Family MembersPMID 27406984Read ↗

Preclinical Anticancer Efficacy of BET Bromodomain Inhibitors Is Determined by the Apoptotic ResponseSemantic proximity Read ↗

Nonselective inhibition of the epigenetic transcriptional regulator BET induces marked lymphoid and hematopoietic toxicity in miceSemantic proximity Read ↗

BET inhibitors synergize with venetoclax to induce apoptosis in MYC-driven lymphomas with high BCL-2 expressionSemantic proximity Read ↗

Targeting BET bromodomain proteins in cancer: The example of lymphomasSemantic proximity Read ↗

Inhibition of BET bromodomain-dependent XIAP and FLIP expression sensitizes KRAS-mutated NSCLC to pro-apoptotic agents.Semantic proximity Read ↗

Targeting MYC dependence in cancer by inhibiting BET bromodomainsSemantic proximity Read ↗

MNT loss in MYC-driven B lymphoma cells enhances apoptosis, inhibits proliferation and increases sensitivity to cancer drugsSemantic proximity Read ↗

Inhibition of Bromodomain Proteins for the Treatment of Human Diffuse Large B-cell LymphomaSemantic proximity Read ↗

Sensitivity of human lung adenocarcinoma cell lines to targeted inhibition of BET epigenetic signaling proteinsSemantic proximity Read ↗

BET inhibitors in the treatment of hematologic malignancies: current insights and future prospectsSemantic proximity Read ↗

BET Bromodomain Inhibition as a Therapeutic Strategy in Ovarian Cancer by Downregulating FoxM1Semantic proximity Read ↗

Lymphoma cells lacking pro-apoptotic BAX are highly resistant to BH3-mimetics targeting pro-survival MCL-1 but retain sensitivity to conventional DNA-damaging drugsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.